UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 23, 2002
Genetronics Biomedical Corporation
| Delaware | 0-29608 | 33-0969592 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
||
| 11199 Sorrento Valley Road, San Diego California | 92121-1334 | |
| (Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number, including area code (858) 597-6006
Not Applicable
| Item 5. Other Events. | ||||||||
| Item 7. Financial Statements and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
| EXHIBIT 99.2 | ||||||||
Item 5. Other Events.
On May 23, 2002, Genetronics Biomedical Corporation issued two press releases related to the planned private placement of special warrants. The first group of special warrants were sold at a price of $0.42 per special warrant, yielding gross proceeds of $3,300,000. The second group of special warrants are to be sold at a price of $0.47 per share and shall yield gross proceeds of $900,000. Exhibits 99.1 and 99.2 are the press releases issued to announce the sale of the special warrants.
Item 7. Financial Statements and Exhibits.
| Exhibit | ||
| No. | Description | |
| 99.1 | Press release issued May 23, 2002 | |
| 99.2 | Press release issued May 23, 2002 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Genetronics Biomedical Corporation | ||
| | ||
| By: | /s/ Avtar Dhillon | |
| Date: May 23, 2002 | Avtar Dhillon, Chief Executive Officer | |
EXHIBIT INDEX
| Exhibit | ||
| No. | Description | |
| 99.1 | Press release issued May 23, 2002 | |
| 99.2 | Press release issued May 23, 2002 |